Finding 949033 (2023-001)

Material Weakness Repeat Finding
Requirement
P
Questioned Costs
-
Year
2023
Accepted
2024-03-06
Audit: 293672
Auditor: Mahoney

AI Summary

  • Core Issue: There is a material weakness in internal controls over financial reporting, highlighted by 12 significant audit adjustments due to errors from an accounting system transition.
  • Impacted Requirements: Nonprofit organizations must adhere to GAAP and ensure accurate financial statements; failure to do so risks material misstatements.
  • Recommended Follow-Up: Management should implement a robust financial statement review process, including monthly reconciliations of key financial items to prevent future issues.

Finding Text

2023-001 Audit Adjustments and Oversight of the Financial Reporting Process Material Weakness Criteria – Nonprofit organizations are required to prepare financial statements in accordance with generally accepted accounting principles (GAAP). Management is responsible for establishing and maintaining internal controls, including monitoring, for the fair presentation in the consolidated financial statements including the notes to consolidated financial statements, in conformity with accounting principles generally accepted in the United States of America. Condition – During the audit for the year ended June 30, 2023, 12 audit adjustments were made that, in the aggregate, were material to the financial statements. The entries mostly were to correct errors that occurred in the accounting system transition which occurred in early 2023. Management reviewed, approved, and accepted responsibility for the audit adjustments before the financial statements were issued. The need for us to record significant audit adjustments indicates a break down in the internal controls related to preparing the Organization’s financial statements. We consider this to be a material weakness because a misstatement of financial statements could occur and not be prevented or detected. Cause – Changes in the accounting systems along with several temporary employees and the change in HR director resulted in some unusual adjustments during the year that were not recorded correctly and not identified before the audit began. Effect – A material misstatement of the financial statements could occur and not be prevented or detected. Recommendation – We recommend management develop and implement a financial statement review and approval process to ensure that necessary adjustments and reconciliations are performed for the consolidated financial statements. This process should include reconciling significant statement of financial position line items to supporting schedules each month, such as bank reconciliations, receivable aging’s, depreciation schedules, etc. Auditee's comments and response – Management agrees with the finding. Management developed and implemented a new financial review process as of February 1, 2024. Responsible party for corrective action: Laura Straw, Finance Director Repeat Finding: Yes, 2022-001

Categories

Internal Control / Segregation of Duties Subrecipient Monitoring Material Weakness Reporting

Other Findings in this Audit

  • 372584 2023-001
    Material Weakness Repeat
  • 372585 2023-001
    Material Weakness Repeat
  • 372586 2023-001
    Material Weakness Repeat
  • 372587 2023-001
    Material Weakness Repeat
  • 372588 2023-001
    Material Weakness Repeat
  • 372589 2023-001
    Material Weakness Repeat
  • 372590 2023-001
    Material Weakness Repeat
  • 372591 2023-001
    Material Weakness Repeat
  • 372592 2023-002
    Significant Deficiency
  • 372593 2023-002
    Significant Deficiency
  • 372594 2023-002
    Significant Deficiency
  • 372595 2023-002
    Significant Deficiency
  • 372596 2023-002
    Significant Deficiency
  • 372597 2023-002
    Significant Deficiency
  • 372598 2023-002
    Significant Deficiency
  • 372599 2023-002
    Significant Deficiency
  • 372600 2023-003
    Significant Deficiency
  • 372601 2023-003
    Significant Deficiency
  • 372602 2023-003
    Significant Deficiency
  • 372603 2023-003
    Significant Deficiency
  • 372604 2023-003
    Significant Deficiency
  • 372605 2023-003
    Significant Deficiency
  • 372606 2023-003
    Significant Deficiency
  • 372607 2023-003
    Significant Deficiency
  • 372608 2023-004
    Material Weakness Repeat
  • 372609 2023-004
    Material Weakness Repeat
  • 372610 2023-004
    Material Weakness Repeat
  • 372611 2023-004
    Material Weakness Repeat
  • 372612 2023-004
    Material Weakness Repeat
  • 372613 2023-004
    Material Weakness Repeat
  • 372614 2023-004
    Material Weakness Repeat
  • 372615 2023-004
    Material Weakness Repeat
  • 372616 2023-005
    Significant Deficiency Repeat
  • 372617 2023-005
    Significant Deficiency Repeat
  • 372618 2023-005
    Significant Deficiency Repeat
  • 372619 2023-005
    Significant Deficiency Repeat
  • 372620 2023-005
    Significant Deficiency Repeat
  • 372621 2023-006
    Significant Deficiency
  • 372622 2023-006
    Significant Deficiency
  • 372623 2023-006
    Significant Deficiency
  • 372624 2023-006
    Significant Deficiency
  • 372625 2023-006
    Significant Deficiency
  • 949026 2023-001
    Material Weakness Repeat
  • 949027 2023-001
    Material Weakness Repeat
  • 949028 2023-001
    Material Weakness Repeat
  • 949029 2023-001
    Material Weakness Repeat
  • 949030 2023-001
    Material Weakness Repeat
  • 949031 2023-001
    Material Weakness Repeat
  • 949032 2023-001
    Material Weakness Repeat
  • 949034 2023-002
    Significant Deficiency
  • 949035 2023-002
    Significant Deficiency
  • 949036 2023-002
    Significant Deficiency
  • 949037 2023-002
    Significant Deficiency
  • 949038 2023-002
    Significant Deficiency
  • 949039 2023-002
    Significant Deficiency
  • 949040 2023-002
    Significant Deficiency
  • 949041 2023-002
    Significant Deficiency
  • 949042 2023-003
    Significant Deficiency
  • 949043 2023-003
    Significant Deficiency
  • 949044 2023-003
    Significant Deficiency
  • 949045 2023-003
    Significant Deficiency
  • 949046 2023-003
    Significant Deficiency
  • 949047 2023-003
    Significant Deficiency
  • 949048 2023-003
    Significant Deficiency
  • 949049 2023-003
    Significant Deficiency
  • 949050 2023-004
    Material Weakness Repeat
  • 949051 2023-004
    Material Weakness Repeat
  • 949052 2023-004
    Material Weakness Repeat
  • 949053 2023-004
    Material Weakness Repeat
  • 949054 2023-004
    Material Weakness Repeat
  • 949055 2023-004
    Material Weakness Repeat
  • 949056 2023-004
    Material Weakness Repeat
  • 949057 2023-004
    Material Weakness Repeat
  • 949058 2023-005
    Significant Deficiency Repeat
  • 949059 2023-005
    Significant Deficiency Repeat
  • 949060 2023-005
    Significant Deficiency Repeat
  • 949061 2023-005
    Significant Deficiency Repeat
  • 949062 2023-005
    Significant Deficiency Repeat
  • 949063 2023-006
    Significant Deficiency
  • 949064 2023-006
    Significant Deficiency
  • 949065 2023-006
    Significant Deficiency
  • 949066 2023-006
    Significant Deficiency
  • 949067 2023-006
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
14.267 Continuum of Care Program $326,522
14.231 Emergency Solutions Grant Program $118,642